Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Sponsor: Shanghai Zhongshan Hospital
Study ID: NCT06796803
Phase: PHASE2/PHASE3
Status: Recruiting

Apply to this trial

Conditions

Potentially Resectable Hepatocellular Carcinoma

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

camrelizumab combined with rivoceranib and HAIC — DRUG
systemic therapy combined with locoregional theraphy as conversion therapy
camerlizumab + rivoceranib — DRUG
systemic therapy

Study Details

The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.

Key Dates

First listed: Jan 28, 2025
Start date: Feb 20, 2025
Status verified: Jul 2026
Primary completion: Feb 20, 2028
Completion: Feb 28, 2030

Study Design

Enrollment: 398 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: camrelizumab + rivoceranib + HAIC
Active Comparator: camrelizumab + rivoceranib

Primary Outcome Measure

R0 rate [ Time Frame: 24 months ]

Central Contacts

Huichuan Sun, MD, PHD
[email protected]
[email protected]